<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Formin-like (FMNL)2 is up-regulated in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> and has been associated with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e>, but little is known about regulatory mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether microRNAs regulate levels of FMNL2 in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We used real-time polymerase chain reaction and immunoblot analyses to measure levels of miR-137, high-mobility group AT-hook (HMGA)1, and FMNL2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and tissue samples from patients (n = 50) </plain></SENT>
<SENT sid="3" pm="."><plain>We used luciferase reporter assays to determine the association between miR-137 and the FMNL2 3' untranslated region, and HMGA1 and the miR-137 promoter </plain></SENT>
<SENT sid="4" pm="."><plain>Chromatin immunoprecipitation assays were used to assess direct binding of HMGA1 to the miR-137 promoter </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: miR-137 and miR-142-3p were predicted to bind FMNL2 based on bioinformatic data </plain></SENT>
<SENT sid="6" pm="."><plain>Only the level of miR-137 had a significant inverse correlation with the level of FMNL2 protein in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and tissues </plain></SENT>
<SENT sid="7" pm="."><plain>FMNL2 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> was targeted by miR-137; expression of miR-137 inhibited proliferation and invasion by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells in vitro, and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">metastasis to liver</z:e> and intestine by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="8" pm="."><plain>HMGA1 bound to the promoter of miR-137 and activated its transcription, which reduced levels of FMNL2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>Ectopic expression of miR-137 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells inhibited phosphorylation of <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) and Akt, which reduced levels of matrix metalloproteinase 2, matrix metalloproteinase 9, and vascular endothelial growth factor; it also reduced invasiveness of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, inhibiting signaling via <z:chebi fb="0" ids="28910">phosphatidylinositol-4,5-bisphosphate</z:chebi> 3-kinase, Akt, and MAPK </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Levels of miR-137 and HMGA1 are reduced, and levels of FMNL2 are increased, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples compared with adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa </plain></SENT>
<SENT sid="11" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, miR-137 targets FMNL2 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> and is regulated by the transcription factor HMGA1 </plain></SENT>
<SENT sid="12" pm="."><plain>Expression of miR-137 reduces <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell invasion in vitro and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts in mice </plain></SENT>
<SENT sid="13" pm="."><plain>FMNL2 appears to activate <z:chebi fb="0" ids="28910">phosphatidylinositol-4,5-bisphosphate</z:chebi> 3-kinase, protein kinase B (Akt), and MAPK signaling pathways </plain></SENT>
</text></document>